Let's have permanently quicker drug approvals

16 June 2021 - New drugs and vaccines likely to increase life expectancy, quality of life and save money, so we ...

Read more →

Put Canadians first by suspending the implementation of harmful drug pricing regulations

4 June 2021 - Innovative Medicines Canada calls on the federal government to suspend the implementation of the Patented Medicines ...

Read more →

Quebec extends public reimbursement of Dupixent (dupilumab) for the treatment of moderate to severe atopic dermatitis to include adolescents

1 June 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec will now apply for Canadians aged ...

Read more →

Campaign launched for life-sustaining treatment access across Canada

31 May 2021 - Alpha-1 Canada publicly launched Access for Alphas today, a campaign aimed at raising the awareness of alfa-1 ...

Read more →

Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis

25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis. ...

Read more →

Quebec announces intention to implement a biosimilar switching policy

18 May 2021 - Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian ...

Read more →

Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars

18 May 2021 - The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta ...

Read more →

Sandoz Canada launches its 6th biosimilar with Inclunox and Inclunox HP (enoxaparin sodium solution for injection 100 mg/mL and 150 mg/mL (high potency))

17 May 2021 - New Sandoz biosimilar launch can potentially lower healthcare costs, especially for Canadian hospitals, as 75% of the ...

Read more →

Long waits for life saving drugs harming Canadians: report

13 May 2021 - Canadians wait 15 months longer on average for new and potentially life-saving medications compared to Americans ...

Read more →

Alberta faces shortage of COVID-19 drug as global demand spikes

11 May 2021 - Provinces with highest case rates hit by shortage of medication for sickest patients. ...

Read more →

Alberta, Canada, begins mandating switches from originator to biosimilar Humira

6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar ...

Read more →

Canadian agency recommends Ruzurgi be reimbursed with conditions

5 May 2021 - CADTH has recommended that Ruzurgi (amifampridine) be reimbursed for the treatment of Lambert-Eaton myasthenic syndrome in ...

Read more →

Bavencio receives reimbursement recommendation from pCODR and INESSS for the maintenance treatment of patients with advanced bladder cancer

29 April 2021 - EMD Serono Canada and Pfizer Canada are pleased to announce that Bavencio (avelumab for injection) has received ...

Read more →

Valeo Pharma’s Redesca and Redesca HP to be covered under the Ontario Public Drug Benefit Program

28 April 2021 - Additional provincial coverage expected to follow. ...

Read more →

Integration of ethical considerations into HTA reports: an analysis of integration levels using a systematic review

26 April 2021 - The objective was to describe the type and level of ethical integration in published health technology assessment ...

Read more →